Clough Capital Partners L P Makes New $1.49 Million Investment in CRISPR Therapeutics AG $CRSP

Clough Capital Partners L P acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,000 shares of the company’s stock, valued at approximately $1,491,000.

Other hedge funds have also recently modified their holdings of the company. Thompson Investment Management Inc. purchased a new position in shares of CRISPR Therapeutics during the third quarter valued at approximately $33,000. Optiver Holding B.V. grew its stake in shares of CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after buying an additional 210 shares during the last quarter. Strategic Wealth Investment Group LLC bought a new position in CRISPR Therapeutics during the 2nd quarter valued at approximately $36,000. Bogart Wealth LLC increased its position in CRISPR Therapeutics by 333.3% during the 3rd quarter. Bogart Wealth LLC now owns 650 shares of the company’s stock valued at $42,000 after buying an additional 500 shares in the last quarter. Finally, Covestor Ltd purchased a new position in CRISPR Therapeutics during the third quarter valued at $48,000. Institutional investors own 69.20% of the company’s stock.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 9,798 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $52.80, for a total value of $517,334.40. Following the completion of the transaction, the chief executive officer owned 235,558 shares of the company’s stock, valued at approximately $12,437,462.40. The trade was a 3.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 2,800 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $52.80, for a total transaction of $147,840.00. Following the transaction, the general counsel owned 87,815 shares in the company, valued at $4,636,632. This represents a 3.09% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 111,677 shares of company stock valued at $6,308,848 over the last quarter. 4.30% of the stock is owned by corporate insiders.

CRISPR Therapeutics Trading Down 0.2%

Shares of CRSP opened at $48.75 on Friday. The business’s fifty day simple moving average is $54.10 and its two-hundred day simple moving average is $57.26. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $78.48. The company has a market cap of $4.68 billion, a price-to-earnings ratio of -7.48 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The business had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The firm’s revenue for the quarter was down 97.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.01) EPS. As a group, research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY‑2025 commercial progress: management reported $116M in FY‑25 revenue driven by CASGEVY, including $54M in Q4, which supports the company’s early commercial trajectory and longer‑term revenue potential. Read More.
• Positive Sentiment: Institutional buying noted: coverage flagged that ARK Invest added CRSP stock, indicating renewed institutional interest that can provide buying support and liquidity. Read More.
• Positive Sentiment: Analyst estimate tweaks: Brookline Capital made small near‑term EPS adjustments (slightly less negative for FY‑2026/FY‑2027), a modest constructive signal for near‑term earnings expectations.
• Neutral Sentiment: Elevated retail interest: Zacks/Yahoo highlighted CRSP among most‑searched stocks — this increases volatility potential but is not a directional fundamental driver. Read More.
• Neutral Sentiment: Short‑interest data appears noisy: recent feeds show inconsistent/zero short‑interest figures (likely data artifacts) and do not provide a clear positioning read.
• Negative Sentiment: Convertible senior notes offering: CRISPR priced an upsized $550M convertible notes deal due 2031. Large convertibles can pressure shares (dilution risk, added supply) and were the proximate cause of a sharp intraday sell‑off. Read More.
• Negative Sentiment: Insider selling: CEO Samarth Kulkarni and General Counsel James Kasinger disclosed sales (roughly 9,798 and 2,800 shares) on March 11th; while routine SEC filings often reflect diversification or scheduled plans, investors frequently interpret such sales as negative near‑term signals. Read More.
• Negative Sentiment: Recent price weakness and volatility: media reported multi‑percent intraday declines following the financing announcement, which can trigger momentum selling and keep downward pressure on the stock. Read More.

Wall Street Analyst Weigh In

Several research firms have commented on CRSP. Chardan Capital boosted their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a report on Saturday, February 14th. TD Cowen lifted their price target on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research report on Friday, February 13th. Citizens Jmp dropped their price target on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research note on Friday, January 30th. Citigroup reissued a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, February 16th. Finally, Needham & Company LLC raised their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, February 13th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average price target of $64.24.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.